Skip to content
OpenCapital
Get started

Cartesian Therapeutics, Inc. RNAC Q2 2025 earnings

Reported August 7, 2025 · Before market open

Revenue$298.0KBeat by $120.4K
EPS$0.50Beat by $1.26
Revenue estimate$177.6K
EPS estimate-$0.76

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$179.7K
EPS estimate-$0.83

Versus estimates

Revenue

Q1 2026$78.0KMiss by $141.8KQ4 2025$947.0KBeat by $796.7KQ3 2025$452.0KBeat by $351.8K
Q2 2025$298.0KBeat by $120.4K
Q1 2025$1.1MBeat by $412.5KQ4 2024$759.0KMiss by $241.0K

Diluted EPS

Q1 2026-$1.46Miss by $0.62Q4 2025-$1.38Miss by $0.56Q3 2025-$1.38Miss by $0.57
Q2 2025$0.50Beat by $1.26
Q1 2025-$0.68Miss by $0.07Q4 2024-$0.59Beat by $0.19

Ask the moment Cartesian Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Cartesian Therapeutics, Inc. report Q2 2025 earnings?
Cartesian Therapeutics, Inc. (RNAC) reported Q2 2025 earnings on August 7, 2025 before market open.
What were Cartesian Therapeutics, Inc.'s Q2 2025 revenue and EPS?
Cartesian Therapeutics, Inc. reported revenue of $298.0K and eps of $0.50 for Q2 2025.
Did Cartesian Therapeutics, Inc. beat estimates in Q2 2025?
Revenue beat the consensus estimate of $177.6K by $120.4K. EPS beat the consensus estimate of $-0.76 by $1.26.
How did Cartesian Therapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 99.1% from $33.4M a year earlier and eps declined 7.4% from $0.54.
Where can I find Cartesian Therapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001453687-25-000099) directly on SEC EDGAR. The filing index links above go to sec.gov.